My Abstract Submissions

A novel BTK gene mutation, T354I, in a patient with X-linked agammaglobulinemia

Custom Content
Applicant Name:

Saghar Sadeghi

Supervisor:

Dr. Amin Kanani

Institution:

UWO

Applicant Information:

Department:

Medicine

Program:

Allergy and Immunology

Phone (Mobile):

(519) 617-5968

Email:

Email hidden; Javascript is required.

Street Address

1523 Coronation Dr

Address

1523 Coronation Dr
Ontario London
Canada
Map It

City
State / Province

Ontario

ZIP / Postal Code

London

Country

Canada

ARE YOU AN:
OR ARE YOU AN:

Fellow-in-Training Associate (FIT)

Would you like to be entered into the Abstract Competition and Poster Judging on Saturday, October 26, 2019?

Yes

If you will be participating in the Abstract Competition and Poster Judging, would you also like to make a 2-minute oral presentation on October 26, 2019?

No

STEP 1: ABSTRACT DETAILS

ABSTRACT TITLE

A novel BTK gene mutation, T354I, in a patient with X-linked agammaglobulinemia

Please choose the category you think most appropriately reflects your abstract content (please note this may be subject to change following review by the Abstract Committee Chairs):

Case Reports

IMPORTANT NOTICE - PUBLICATION STATUS

Has the work outlined in this abstract been published or accepted for publication elsewhere prior to June 28, 2019?

No

If Yes, Where was the abstract published or accepted for publication?

Citation:
Date:
Comments
STEP 2: CONFLICT OF INTEREST DISCLOSURES

Conflict of Interest Note


Disclosure should include any relationship that may bias your presentation or that, if known, could convey the perception of bias. This policy allows the meeting participants to be fully knowledgeable in evaluating the information being presented.

This Conflict of Interest declaration will be completed by the first/presenting author on behalf of all co-authors

Presenting authors, please also complete and submit the Author Disclosure Form.

Do any of the co-authors on this abstract declare a conflict of interest?

No

Names & Relationships:
Conflicts of Interest Declaration - Confirmation
All conflicts of interest have been declared for this abstract’s authors/co-authors.
No Conflict of Interest Declaration - Confirmation
  • None of the authors/co-authors on this abstract declare a conflict of interest
None of the authors/co-authors on this abstract declare a conflict of interest

INDUSTRY SUPPORT

Industry Support

This project received industry support.

No

Name of industry support
Industry Support Declaration - Confirmation
All sources of industry support have been declared.
No Industry Support Declaration - Confirmation
  • This research was not supported by industry.
This research was not supported by industry.

STEP 3: REQUIRED - CONSENT TO PUBLISH

Consent to Publish info

If the abstract contains details relating to individual participants (for example a case report), written informed consent for the publication of these details must be obtained from the participants and a statement to this effect should appear at the end of the abstract.

Our guidelines for consent statements can be found here: https://www.biomedcentral.com/getpublished/editorial-policies#Ethics.

If the patient is deceased, consent for publication should be obtained from the next of kin. If the patient is under 18, consent should be obtained from the parent or guardian.

Upload Signed Consent Forms Here

Consent-Form.pdf

I agree to the following statements:

I agree to the following statements:

  • I understand that if accepted, this abstract becomes the property of the CSACI. Ownership of submitted abstracts that are not accepted reverts to the authors.
  • I affirm that the abstract submitted has not been and will not be published on or before June 28, 2019, (unless otherwise disclosed above).
  • On behalf of all authors of this abstract, and to the best of my knowledge, I affirm that all information in this abstract is reported as accurately as possible.
  • I understand that the CSACI has a policy on the discussion of unlabeled uses of Health Canada regulated products. This policy requires me to disclose to the audience at the time of presentation any references to such unlabeled uses. I agree to do so in any presentation resulting from the submission of this abstract.
  • I affirm that I have read and understood the Abstract Guidelines document.
  • All author/co-author conflicts of interest and financial relationships have been declared.
Please submit your abstract(s) and consent form here: (MAX 300 Words)

A-novel-BTK-gene-mutation.docx

Signature

Date

09-06-2019

End of Form Message

Complete and return application form no later than Friday, June 28, 2019.

An e-mail response will be sent confirming receipt.

My Author Disclosure Submissions